Shanghai Junshi Biosciences Co., Ltd. provided consolidated earnings guidance for the year ended 31 December 2020. The company is estimated that the operating revenue for 2020 will be approximately RMB 1,590 million, representing an increase of about RMB 814.9108 million compared with the same period of the previous year or a year-on-year increase of approximately 105.14%. The net loss attributable to the owners of the parent company for 2020 will be approximately RMB 1,644 million, representing an increase in loss of approximately RMB 896.5822 million compared with the same period of the previous year or a year-on-year increase of approximately 119.96%.